within Pharmacolibrary.Drugs.ATC.A;

model A10BD16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 1300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013833333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and canagliflozin is a fixed-dose combination medication used for the treatment of type 2 diabetes mellitus in adults. Metformin is a biguanide antihyperglycemic agent primarily used to improve glycemic control by decreasing hepatic glucose production and increasing insulin sensitivity, while canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidney, resulting in increased urinary glucose excretion. This combination is currently approved and marketed for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for average healthy adults, as direct pharmacokinetic parameterization of the fixed-dose combination is not available in publication. Parameters for each component are approximated from studies of individual drugs. Estimated for oral administration of metformin (1000 mg) and canagliflozin (300 mg).</p><h4>References</h4><ol><li><p>Devineni, D, et al., &amp; Usiskin, K (2015). Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. <i>Clinical pharmacology in drug development</i> 4(3) 226–236. DOI:<a href=\"https://doi.org/10.1002/cpdd.166\">10.1002/cpdd.166</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27140803/\">https://pubmed.ncbi.nlm.nih.gov/27140803</a></p></li><li><p>Donnan, K, &amp; Segar, L (2019). SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. <i>European journal of pharmacology</i> 846 23–29. DOI:<a href=\"https://doi.org/10.1016/j.ejphar.2019.01.002\">10.1016/j.ejphar.2019.01.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30639796/\">https://pubmed.ncbi.nlm.nih.gov/30639796</a></p></li><li><p>Murphy, J, et al., &amp; Devineni, D (2015). Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. <i>International journal of clinical pharmacology and therapeutics</i> 53(3) 256–264. DOI:<a href=\"https://doi.org/10.5414/CP202233\">10.5414/CP202233</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25546166/\">https://pubmed.ncbi.nlm.nih.gov/25546166</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD16;
